Contrad Swiss SA

Contrad Swiss is a leading pharmaceutical company in the field of regenerative medicine. Our primary objective is to pioneer advanced therapeutic solutions that have the potential to transform current medical approaches. The main innovation is the 500Line, a research-supported product line for effective pain management.

Our comprehensive portfolio also includes the advanced aesthetic range, ACTV8SKN™ line and Egyfil, alleviating lotion.
All our product lines are powered by SIGMOLECS® Technology that amplifies the therapeutic potential of peptides.
Sequenced for precision, SIGMOLECS® can be adapted to diverse delivery systems, working in harmony with the body's natural physiological pathways.
SIGMOLECS® peptides rapidly penetrate the epidermis and assist with penetration of other biomolecules, such as HA.
SIGMOLECS® talks to the cells in their language.